Image Analysis Group (IAG) and Better Medicine announced a strategic partnership on July 10, 2025, to integrate Better Medicine’s AI analytics into IAG’s DYNAMIKA platform for faster, cost-efficient central reads in oncology trials.13
The collaboration enables AI-assisted tumor detection, segmentation, and measurement, reducing manual workload, turnaround times, and costs while maintaining regulatory compliance.1
Dr. Olga Kubassova, CEO of IAG, highlighted the partnership's role in accelerating drug development.1
Priit Salumaa, CEO of Better Medicine, noted it expands their AI tools to clinical trial workflows for better cancer research outcomes.1
Benefits include streamlined workflows, lower imaging costs, and support for multi-phase oncology studies across solid tumors.1
Sources:
1. https://www.ia-grp.com/news/news-iag-better-medicine-ai-oncology-imaging/